Lifting helps sarcopenia, but the gains are smaller than you would hope

Sarcopenia, the age-related loss of muscle mass and strength, undermines independence, walking speed and everyday function in later life. Resistance training is the standard recommendation for managing it, yet the guidance behind that recommendation has stayed vague: how often, what kind of resistance, and how much per week remain open questions. This review set out to test not just whether lifting helps older adults who already carry a sarcopenia diagnosis, but whether the improvements are large enough to matter in daily life, and whether an optimal weekly dose of training can be identified from the trial evidence.

The authors searched PubMed, Embase, Web of Science and CENTRAL up to June 2025 for randomised controlled trials in adults aged 60 or over with diagnosed sarcopenia, comparing resistance training against usual care or no intervention. Eligible trials had to report outcomes on strength, physical function or muscle mass. Twenty-four trials with 951 participants were included. Risk of bias was assessed with the RoB 2 tool, results were pooled with random-effects models, and Bayesian dose-response models were fitted to estimate how outcomes changed with weekly training dose measured in MET-minutes.

Resistance training significantly improved handgrip strength, gait speed, knee extension strength, timed up and go performance and the five-times sit-to-stand test. However, no significant improvements emerged for the short physical performance battery or for appendicular skeletal muscle mass, meaning the muscle itself did not measurably grow. Crucially, the gains in grip strength, gait speed and the functional tests did not exceed the thresholds for a minimally important difference, which the authors interpret as little to no clinical benefit on average. Dose modelling suggested an optimal dose of 1220 MET-min per week for handgrip strength, while 600 MET-min per week may suffice for meaningful gait speed improvement. Resistance type and training frequency emerged as key effect modifiers.

The direction of these results confirms what guidelines already say: resistance training probably improves strength and physical function in sarcopenic older adults. The size of the results complicates that message, because average gains fell below the bar for changes patients would notice, and muscle mass, the defining feature of sarcopenia, did not shift. The dose-response modelling is a genuinely new contribution, offering the first estimates of minimal and optimal weekly training doses in this population. Open questions remain about which resistance types and frequencies work best, since subgroups differed but the analysis could not pin down why.

For anyone thinking about ageing muscle, this is a reason to see lifting as genuinely useful but not a dramatic fix once sarcopenia has taken hold: strength and function improved consistently, just modestly. It is also a reason to think the details of a programme matter, since how often people trained and what kind of resistance they used modified the results. The finding that a lower weekly dose may be enough for walking speed, while grip strength appeared to want more, hints that different goals may respond to different amounts of training. None of this is a prescription, but it argues for consistency over heroics.